Biosensors

Biosensors: Nomura maintains Buy with $1.50 TP. Note that grp emerging as a credible new force in a competitive landscape traditionally dominated by US med-tech giants. Following approval of Nobori, believe further re-rating will be underpinned by several catalysts such as continued momentum in forthcoming results, potential value-unlocking of its China assets, and regulatory approvals for BioFreedom and SFDA approval for BioMatrix.